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Summary
To identify the molecular signatures that predict responses to decitabine (DAC), we examined baseline gene mutations (28 target genes) in 109 myelodysplastic syndrome (MDS) patients at diagnosis. We determined that TP53 mutations predicted complete response (CR), as 10 of 15 patients (66Á7%) who possessed TP53 mutations achieved a CR. Univariate and multivariate analyses showed that TP53 mutations are the only molecular signatures predictive of a CR to DAC in MDS. Among the ten patients with TP53 mutations who achieved a CR, nine presented with complex karyotypes due to abnormalities involving chromosome 5 and/or chromosome 7, and eight possessed monosomies. Although TP53 mutations were associated with a higher frequency of CRs, they were not associated with improved survival. Poor outcomes were attributed to early relapses and transformation to acute myeloid leukaemia after CR. Post-DAC therapy patient gene mutation profiles showed that most CR patients exhibited fewer gene mutations after achieving a CR. It seems that suppression of these gene mutations was facilitated by DAC, resulting in a CR. In summary, TP53 mutations might predict decitabine-induced complete responses in patients with MDS. DAC-induced responses may result from partial suppression of malignant clones containing mutated TP53 genes.
Keywords: TP53 mutation, decitabine, prediction, myeloproliferative, myelodysplasia. Decitabine (DAC) , an important hypomethylation agent (HMA), was approved for treatment of myelodysplastic syndrome (MDS) in 2006 (Steensma et al, 2009 ). More than 50% of patients treated with DAC experience haematological improvement (HI), and approximately 30% of patients achieve a complete response (CR) (Lubbert et al, 2011; Li et al, 2014) . The number of effective methods of identifying patients who are most likely to respond to treatment with HMAs is limited. Clinical and experimental variables, such as the chronic myelomonocytic leukaemia (CMML) subset and special karyotypes (involving chromosome 7 abnormalities), may enable patient stratification according to response rates (Aribi et al, 2007; Kantarjian et al, 2007a; Raj et al, 2007) , but these models are not sufficiently conclusive. Better molecular signatures of HMA responsiveness are needed.
Several recurrent somatic mutations have been identified in patients with MDS, and some of these mutations have been linked to clinical variables, including overall survival . Because gene mutations underlie the pathogenic mechanisms driving the initiation and progression of MDS, they may also represent potential molecular biomarkers of drug sensitivity or resistance. Some related papers (Bejar et al, 2014; Traina et al, 2014; Kim et al, 2015) have identified point-specific molecular signatures; for example, the TET2 mutation (>10% mutation loads and not associated with ASXL1 mutations) was predictive of a better response to HMAs and longer survival.
We surmised that individual gene mutations might serve as molecular signatures of responsiveness in MDS patients treated with DAC. We performed next-generation target sequencing to define 28 recurring gene mutations in disease samples from 109 MDS patients who were treated with DAC to examine the associations between mutational patterns of different mutant alleles and responses to DAC treatment and overall survival. More importantly, we analysed changes in patient gene mutation profiles after achievement of a CR (16 research paper First published online 16 December 2016 doi: 10.1111/bjh.14455 patients) or no response/disease progression (NR/PD, 7 patients).
Patients and methods

Patient samples and response assessment
A total of 109 MDS patients treated with DAC were retrospectively analysed in this study. Enrolment (beginning of DAC therapy for each individual) occurred between September 2009 and November 2014, and the median observation duration was approximately 37 months. All samples were obtained from patients treated at the Department of Haematology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital. Informed consent was obtained from all subjects according to institutional review board-approved protocols, which were carried out in accordance with the Declaration of Helsinki. All experiments were approved by the Ethics Committee of Shanghai Jiao Tong University Affiliated Sixth People's Hospital. All methods used in this study were performed in accordance with approved guidelines. In addition to the MDS subsets defined according to the World Health Organization (WHO) 2008 classification (Vardiman et al, 2009) , we included patients with refractory anaemia with excess blasts in transformation (RAEBt) and CMML, because the US Food and Drug Administration (FDA) suggested that all MDS patient subsets included in the FrenchAmerican-British (FAB) classification (Bennett et al, 1982) should be candidates for DAC therapy. Response to treatment was assessed using the International Working Group (IWG) Response Criteria, which were revised in 2006 (Cheson et al, 2006) . Patients diagnosed as having experienced a CR, partial response (PR), marrow CR (mCR) or HI were considered "responders," while patients diagnosed as having experienced no response or disease progression were considered "nonresponders." When necessary, comparisons were made between CR and incomplete response (non-CR) subsets.
Sample processing and next-generation sequencing
Bone marrow (BM) samples were harvested from patients before (109 patients) and after (16 CR and 7 NR/progressive disease [PD] patients) DAC treatment. BM mononuclear cells (BMNCs) were isolated using Ficoll solution (Lymphoprep TM, Oslo, Norway). Genomic DNA was isolated using a TIANamp Genomic DNA Kit (TIANGEN, Beijing, China), according to the manufacturer's instructions. Next-generation sequencing was carried out for 28 genes using a MiSeq Benchtop Sequencer (Illumina, San Diego, CA, USA), as previously reported . These genes were found to exhibit recurrent mutations via previous whole-exome sequencing and were also related to cancer development. To identify the recurrent mutations in these genes, we designed polymerase chain reaction (PCR) primers using the primerXL pipeline pipeline (http://www.primerxl.org/). A total of 550 oligonucleotide pairs covered all of the coding sequences (CDS) and most of the untranslated regions (UTRs) of the 28 genes. PCR was carried out on an AB 2720 Thermal Cycler (Life Technologies Corporation, Carlsbad, CA, USA) under the following cycling conditions: (i) 95°C for 2 min; (ii) 11 cycles of 94°C for 20 s, 63°C-0Á5°C for 40 s, and 72°C for 1 min; (iii) 24 cycles of 94°C for 20 s, 65°C for 30 s, and 72°C for 1 min; and (iv) 72°C for 2 min. PCR generated libraries for further detection. Then, DNA adapters were ligated, and the indexed fragments from 10 libraries were pooled and hybridized. After the sequencing primer was hybridized, base incorporation was carried out in a single lane on a MiSeq Benchtop Sequencer (Illumina), according to the manufacturer's standard cluster generation and sequencing protocols for 250 cycles of sequencing per read to generate paired-end reads, which included 250 bp at each end and an 8-bp index tag. Variants present in databases of normal genomes [1000 Genomes Project (http:// www.1000genomes.org) or ESP6500 (http://evs.gs.washington.edu/EVS)] at a population frequency of 0Á1% or more were discarded. The remaining variants were considered candidate somatic mutations.
Statistical methods
Statistical analyses were conducted with SPSS software, version 17.0 (SPSS, Inc., Chicago, IL, USA). Categorical variables were compared using Fisher's exact test or v 2 test as appropriate. Survival curves were prepared via the KaplanMeier method and compared via the log-rank test. Multivariate Cox proportional hazards models were used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs) of association pertaining to the relationship between risk factors and survival. Logistic regression was conducted to elevate the factors predicting DAC responses. All reported P values were 2-sided and considered significant at 0Á05.
Results
Patient characteristics and general responses to DAC therapy
The characteristics of the 109 patients who underwent baseline target gene sequencing and received DAC therapy are shown in Table I . Their median age was 61 years, and the ratio of males to females was 1Á9. Among these 109 patients, 70Á6% had RAEB1,RAEB2,RAEB-t or CMML (77 cases 
Predicting the effects of baseline gene mutations on DAC response
The spectrum of mutations in 109 patients is shown in Fig 1. Ninety-four of 109 patients (86Á2%) exhibited at least one baseline gene mutation before DAC therapy. The gene mutations with a frequency over 10%, including DNMT3A (15Á6%), ASXL1 (14Á7%), U2AF1 (13Á8%), TP53 (13Á8%), ITIH3 (11Á9%), TET2 (11Á9%), and IDH1/IDH2 (10Á1%), were similar to those of previous reports . When responders and nonresponders were compared, no somatic mutations correlated significantly with DAC response (Table SI) . In contrast, when we compared the effects of gene mutations on patients who achieved a CR with those on patients who did not achieve a CR, TP53 mutations were identified as the only mutation that could predict a CR (Table SII) . Although we had assumed that more patients with TP53 mutations carried poor karyotypes, 66Á7% (10/15 cases) of these patients achieved a CR (P = 0Á001). Interestingly, 9 of 10 patients with TP53 mutations who achieved a CR presented with baseline complex karyotypes that involved abnormalities on chromosome 7 and/or chromosome 5. Additionally, 8 of the patients who achieved a CR presented with baseline complex karyotypes with monosomies. Nine of the 11 patients (82%) (9/11 patients) with TP53 mutations who exhibited complex karyotypes achieved a CR, while 80% of patients with TP53 mutations who had monosomies achieved a CR (Table SIII) . Both univariate and multivariate analysis showed that TP53 mutations were the only molecular signatures that could predict DAC-induced CRs (Table SIV) [univariate P = 0Á001; multivariate P = 0Á014, HR = 5Á50 (95% CI 1Á42-21Á33)]. When we constructed a baseline gene mutation profile for 15 patients carrying the TP53 mutation ( Figure S1 ), we could not identify any diversity with respect to the numbers of mutated genes, components or variant allele frequencies (VAFs) among the ten patients who achieved a CR and the five patients with NR/PD after DAC therapy.
Predicting the effects of baseline gene mutations on overall survival
We explored the relationship between baseline mutation status and overall survival in a subset of patients with available survival data. Eight patients who underwent HSCT after (Vardiman et al, 2009) . †Classified according to the French-American-British classification (Bennett et al, 1982) .
DAC were excluded from our analysis. The median followup for the remaining 101 patients was 32 months (95% CI 25Á2-38Á8). Despite its association with CR, the TP53 mutation was linked to poor overall survival (P = 0Á072) (Fig 2A) . CR patients with baseline TP53 mutations had a much shorter median survival than those without baseline TP53 mutations (14 vs. 39 months; P = 0Á012, Fig 2B) . We also analysed the differences in the incidence of relapse and time to transformation to AML in CR patients with and without TP53 mutations. The results showed that CR patients carrying TP53 mutations survived for significantly shorter periods until relapse or development of AML than patients without TP53 mutations (Fig 2C and D) . Additionally, despite not being associated with DAC response, IDH1/2 mutations were associated with poor overall survival (Fig 2E) . In univariate analysis, IDH1/2 mutations appeared to be an adverse prognostic factor for OS (HR, 2Á42; 95% CI, 1Á02-5Á74; P = 0Á026). Monosomies were linked to poor overall survival in in univariate analysis and multivariate analysis (Table SV) .
Changes in mutated gene profiles after DAC therapy
Next-generation sequencing was performed on whole DNA from BM samples of 16 patients who achieved a CR (with or without continuous CR) and 7 patients with NR/PD after DAC therapy. Figure 3 and Table II illustrate the changes in the numbers of gene mutations, components and VAFs before and after DAC therapy. First, some mutations became undetectable after DAC therapy (12/14 CR patients vs. 3/7 NR/PD patients, P = 0Á12, five of the 7 patients presented with undetectable TP53 mutations after DAC), Second, the numbers of gene mutations decreased more frequently among CR patients than among NR/PD patients (12/14 CR vs. 2/7 NR, P = 0Á017). Third, among CR patients, VAFs were reduced by more than 50% in 18 of 30 mutations (66Á7%), while among NR/PD patients, VAFs were reduced by more than 50% in only 3 of 13 mutations (23Á1%) (P = 0Á045). Additionally, some other interesting findings were noted. First, the decay or disappearance of a single driver mutation (such as TP53, CR2 and CR5; TET2, CR3; and U2AF1, CR10) could result in a CR, although other co-existing mutations could be present. Moreover, the spectrum of gene mutations before and after DAC therapy indicated that double-or multi-clonal haematopoiesis was a recurrent event in MDS. Finally, with five exceptions CR1,CR4,CR6,CR8 and CR12 all patients who achieved a CR retained at least one gene mutation after achieving CR, which means that some residual gene mutations did not resist the acquisition of morphological CRs. Hence, although DAC induced morphological CRs (even with cytogenetic CRs), it did not eliminate all malignant clones. The five CR patients without detectable residual gene mutations relapsed clinically within 5 months after DAC-induced CR, although DAC was used continuously in these patients.
Discussion
To acquire the above results, we examined bone marrow samples from 109 MDS patients before DAC treatment and also examined 28 genes that are known to be mutated in MDS. Using sensitive quantitative sequencing techniques, we were able to identify at least one mutation in 86Á2% (94/109) of patients. The overall response rate (ORR) and CR rate in this assay were 67Á9% (74 patients) and 27Á5% (30 patients), respectively, which were very close to those of previous large cohort studies (Kantarjian et al, 2007b; Muller-Thomas et al, 2014) . Although all patients achieved a complete response (CR), patients with baseline TP53 mutations exhibited shorter median survival than those without TP53 mutations (14 vs. 39 months; P = 0Á012). Among the 27 patients who achieved a CR after decitabine therapy, those with TP53 mutations survived significantly shorter periods until (C) relapse (6 vs. 9 months; P = 0Á035) and (D) progressed more rapidly to acute myeloid leukaemia (15 vs. 48 months; P = 0Á041) than wild-type TP53 patients. (E) Ten patients with baseline IDH1/2 mutations exhibited significantly shorter overall survival (13 months) than those without IDH1/2 mutations (20 months) (P = 0Á026). MT, mutated; WT, wildtype. [Colour figure can be viewed at wileyonlinelibrary.com] The TP53 gene is located on chromosome 17p and plays a critical role in various oncogenetic pathways (Muller & Vousden, 2014) . TP53 mutations often occur in MDS/AML patients with 17p deletions or complex karyotypes involving abnormalities on chromosomes 5 and/or 7 (Volkert et al, 2014; Ok et al, 2015) . It has been deduced that the gene instability associated with complex karyotypes is frequently caused by TP53 mutations (Jasek et al, 2010) . In our study, TP53 mutations were associated with increases in CRs to DAC therapy, particularly in individuals with TP53 mutations and complex karyotypes (involving abnormalities on chromosomes 5 and/or 7 or containing monosomies) (Table S3 ). Other studies (Gao et al, 2015; Lubbert et al, 2016) have reported higher levels of responsiveness toward DAC among MDS patients with poor karyotypes (complex karyotypes, chromosome 7 abnormalities, or monosomies). Because TP53 mutations frequently coincide with complex karyotypes, it is understandable that MDS patients with TP53 mutations are especially sensitive to DAC therapy. MDS patients with TP53 mutations exhibited a response rate of only 8% to cytotoxic treatments whereas patients with wild-type TP53 exhibited a response rate of 60% (Wattel et al, 1994) . DAC can produce TP53-independent cell cycle exits by reversing aberrant epigenetic repression of differentiation genes in cancer cells (Ng et al, 2011; Saunthararajah et al, 2015) . This may partly explain the good response to DAC among TP53-mutated MDS patients. Some similar analyses have yielded similar results; i.e., although patients Table II . *Patients whose karyotype was normal before DAC treatment. Thus, they could not experience a CCR after treatment.
#
Patients whose karyotype was abnormal before DAC treatment. However, they did not experience a CCR after DAC treatment. CCR, complete cytogenetic response; CR, complete response; NR, no response; PD, progressive disease. (Muller-Thomas et al, 2014) . In contrast to the finding by Bejar et al (2014) , we found that patients with TET2 mutations did not exhibit better responses to DAC therapy. These results may be attributed to relatively small sample sizes and the co-existence of TET2 mutations with other mutations. Figure 3 presents two interesting cases (CR3 and CR7) whose loss of TET2 mutations result in a CR, regardless of the presence co-existing mutations, suggesting that TET2 influences DAC treatment outcomes. Similar to the results of the study by Bejar et al (2014) , our study did not identify specific mutations that were strongly associated with a lack of response to treatment. Therefore, it was reasonable for Bejar et al (2014) to propose that mutation information alone should not be used as a basis for foregoing therapy with an HMA if treatment is indicated.
Survival data were collected for the 109 patients in our cohort. To exclude the influence of confounding factors, we excluded 8 patients who underwent HSCT after DAC therapy. We found that the TP53 mutation profiles that were predictive of a CR to DAC were not associated with better survival (Fig 2A) . When we compared survival between CR patients with and without original TP53 mutations, we noted much shorter median survival among patients carrying TP53 mutations than among those without TP53 mutations (Fig 2B) . Further analysis suggested that a significantly shorter period until relapse or AML transformation was responsible for the poor outcomes noted among patients with TP53 mutations (Fig 2C and D) . Univariate analysis showed that IDH1/2 mutations were associated with shorter overall survival (Fig 2E) , a finding consistent with those of previous reports (Kosmider et al, 2010; Thol et al, 2010) . The above findings indicate that some baseline gene mutations may be considered indicators of DAC therapeutic benefits (response or survival). Studies with expanded sample sizes are necessary to validate these results.
We first compared the changes in the gene mutation profiles before and after DAC therapy of the 16 patients who achieved a CR with those of the 7 NR/PD patients (Fig 3) . Some gene mutations became undetectable or the VAFs decreased in those patients who achieved a CR. TP53 mutations became undetectable in five of the seven CR patients after DAC therapy (Line 1 in Fig 3) , and the VAF decreased in another patient. These findings suggest that DAC therapy at least partly suppressed malignant clonal cells, either by reactivating tumour suppressor genes (TSGs) or by directly killing cells. However, residual gene mutations were still present in some patients who achieved a CR. And some of the CR patients who had been without detectable gene mutations relapsed afterwards, even when DAC was used continuously. Thus, the CRs facilitated by DAC therapy did not eliminate all malignant clones, so these responses were not permanent. Interestingly, based on the gene mutation profiles before and after DAC, we found that double-or multi-clonal haematopoiesis was a recurrent event in MDS. It is conceivable that different malignant clones in MDS marrow may compete with one another in addition to competing with residual normal haematopoietic cells. The results of these competitions determine the clinical features and final outcomes of MDS patients.
In summary, a large cohort of next-generation targeted sequencing results showed that TP53 mutations were the only predictors of DAC-induced complete responses. However, CRs did not result in longer survival due to early relapses and AML transformation. While DAC therapy improved patient gene mutation profiles, these improvements were not permanent. 
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